MABVAX THERAPEUTICS HLDGS INC
MBVX
MBVX was delisted on the 10th of July, 2018.
2 hedge funds and large institutions have $4K invested in MABVAX THERAPEUTICS HLDGS INC in 2018 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
73% less capital invested
Capital invested by funds: $15K → $4K (-$11K)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$1.1K |
Top Sellers
MBVX Hedge Fund Activity: Q4 2018 in Review
2 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in MABVAX THERAPEUTICS HLDGS INC (MBVX) for Q4 2018, worth a combined $4K — down 73% from $15K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new MBVX positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Panagora Asset Management, adding an estimated $1.1K.
- 2 institutional investors held MABVAX THERAPEUTICS HLDGS INC (MBVX) as of Q4 2018, unchanged from Q3 2018.
- Funds reported $4K of MABVAX THERAPEUTICS HLDGS INC stock for Q4 2018, down 73% quarter-over-quarter.
- 1 fund opened new MABVAX THERAPEUTICS HLDGS INC positions in Q4 2018 and 0 closed out, a net change of +1 holder.
- The largest MABVAX THERAPEUTICS HLDGS INC buyer in Q4 2018 was Panagora Asset Management, an estimated $1.1K added.
Based on aggregated 13F filings for Q4 2018.